BioCryst制药(BCRX)今日股价盘中大跌16.90%,引发市场广泛关注。公司最新公布的2024年第三季度业绩显示,营收同比增长35%至1.17亿美元,但调整后每股亏损7美分,高于分析师平均预期的6美分亏损,也未达华尔街预期区间。
作为一家专注于开发新型小分子药物治疗感染和炎症疾病的生物技术公司,业绩疲软往往会引发市场对公司长期增长前景的担忧。虽然分析师对该股仍然维持较高评级,但低于预期的财报数据或成为当日股价大跌的主要原因。
不过也有分析人士认为,当前股价剧烈波动可能还与大资金的资金流出有关。根据数据,近期该股大资金净流出达1000万美元,整体资金净流出3000万美元。但具体导致股价重挫的原因,还需进一步观察和分析。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.